Bristol Projects Opdivo Sales Will Grow Again In 2021
With new Opdivo/Yervoy combination data in first-line lung cancer, the company expects the PD-1 inhibitor’s growth to go from flat to rising in 2021. Bristol’s and Celgene’s third quarter earnings exceeded expectations and their merger is on track to close this year.
You may also be interested in...
More lung cancer patients treated with neoadjuvant Opdivo plus chemotherapy had a pathologic complete response than those who received chemo alone. BMS will discuss the results with regulators.
Bristol Myers Squibb brought in $500m from customers that overbought in case of drug shortages, but first quarter sales still grew 8% excluding those purchases and BMS projects growth through 2021.
The company believes the PD-1 inhibitor’s recent declines will be reversed through new indications, providing revenue growth along with other new products by the time Revlimid faces generics in 2022.